Pamidronate-induced tubulointerstitial nephritis with Fanconi syndrome in a patient with primary hyperparathyroidism.

Pamidronate disodium (Aredia) is a member of the class of biphosphonates, widely used in the treatment of malignancy-associated osteolytic lesions and osteoporosis. At the recommended doses, renal toxicity of biphosphonates is very infrequent [1–3]. However, higher doses have produced nephrotoxicity in animal models [4,5]. More recently, the nephrotic syndrome with renal failure has also been reported in a few patients treated with pamidronate [6,7]. We describe a case of severe tubulointerstitial nephritis with Fanconi syndrome induced by intravenous pamidronate in a patient with primary hyperparathyroidism.